Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus

OBJECTIVES: High rates of anti-drug antibodies (ADA) to rituximab have been demonstrated in patients undergoing treatment for SLE. However, little is known with regard to their long-term dynamics, impact on drug kinetics and subsequent implications for treatment response. In this study, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wincup, Chris, Dunn, Nicky, Ruetsch-Chelli, Caroline, Manouchehrinia, Ali, Kharlamova, Nastya, Naja, Meena, Seitz-Polski, Barbara, Isenberg, David A, Fogdell-Hahn, Anna, Ciurtin, Coziana, Jury, Elizabeth C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321108/
https://www.ncbi.nlm.nih.gov/pubmed/36370065
http://dx.doi.org/10.1093/rheumatology/keac608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321108/
https://www.ncbi.nlm.nih.gov/pubmed/36370065
http://dx.doi.org/10.1093/rheumatology/keac608

Ejemplares similares